表观遗传学
RNA甲基化
甲基化
背景(考古学)
核糖核酸
心肌病
生物
N6-甲基腺苷
DNA甲基化
小RNA
生物信息学
纤维化
甲基转移酶
癌症研究
遗传学
医学
基因
心力衰竭
基因表达
病理
内科学
古生物学
作者
Li Liu,Linxing Yu,Y Wang,Liufang Zhou,Yan Liu,Xingshou Pan,Jianjun Huang
标识
DOI:10.1016/j.phrs.2024.107305
摘要
Cardiomyopathy (CM) represents a heterogeneous group of diseases primarily affecting cardiac structure and function, with genetic and epigenetic dysregulation playing a pivotal role in its pathogenesis. Emerging evidence from the burgeoning field of epitranscriptomics has brought to light the significant impact of various RNA modifications, notably N6-methyladenosine (m6A), 5-methylcytosine (m5C), N7-methylguanosine (m7G), N1-methyladenosine (m1A), 2′-O-methylation (Nm), and 6,2′-O-dimethyladenosine (m6Am), on cardiomyocyte function and the broader processes of cardiac and vascular remodelling. These modifications have been shown to influence key pathological mechanisms including mitochondrial dysfunction, oxidative stress, cardiomyocyte apoptosis, inflammation, immune response, and myocardial fibrosis. Importantly, aberrations in the RNA methylation machinery have been observed in human CM cases and animal models, highlighting the critical role of RNA methylating enzymes and their potential as therapeutic targets or biomarkers for CM. This review underscores the necessity for a deeper understanding of RNA methylation processes in the context of CM, to illuminate novel therapeutic avenues and diagnostic tools, thereby addressing a significant gap in the current management strategies for this complex disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI